Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life ...

UBS raised the firm’s price target on Sight Sciences (SGHT) to $12 from $7 and keeps a Buy rating on the shares. Medicare Administrative Contractors Novitas and First Coast Service Option established ...

This low-cost mission is still only getting started, and it's taking bigger risks than typical big-ticket NASA missions.

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Wave Life Sciences (WVE) to $30 from $22 and keeps a Buy rating on the shares. The firm says its key opinion leader validation and ...

BTIG analyst Mark Massaro lowered the firm’s price target on Exact Sciences (EXAS) to $65 from $82 and keeps a Buy rating on the shares. The company delivered a Q3 revenue miss and large guide-down, ...

Canaccord raised the firm’s price target on Exact Sciences (EXAS) to $95 from $75 and keeps a Buy rating on the shares. The firm said they are bullish heading into earnings and 2025 as recent weakness ...

CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human ...

Kodiak Sciences (KOD) has priced an expanded public offering of approximately 6.96 million shares at $23.00 each. The company expects to raise roughly $160 million in gross proceeds. Kodiak Sciences ...

Price stabilization mechanisms (PSMs), one of a set of key policy elements aiming at supporting increasing and stable carbon prices, may affect the performance of emissions trading systems (ETS) in ...

Integral Ad Science Holding Corp. IAS will release its financial results for the fourth quarter, before the opening bell, on Friday, Feb. 28, 2025. Analysts expect the New York-based company to report ...